Medication info
Sitagliptin 50 mg Tablets (Sitagliptin Hydrochloride Monohydrate)

Sitagliptin 50 mg Tablets (Sitagliptin Hydrochloride Monohydrate)

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›56.7mg / 1 tablet
Manufacturer / importer
Aliko Pharmaceutical Co., Ltd.
Appearance
Light apricot-colored, round, biconvex film-coated tablets
Packaging
PTP - 28 tablets/box [(14 tablets/PTP×2)]
Approval status
Active

MFDS item code 202101320 · Approved 2021.02.16 · Insurance code 656005350

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
This medicine is administered at a dose of 100 mg once daily, either as monotherapy or in combination therapy; the maximum daily dose is 100 mg. This medicine may be taken with or without food. When administered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). Patients with renal impairment Because dosage adjustment according to renal function is required, assessment of renal function is recommended before starting treatment with this medicine and periodically thereafter. 1. No dosage adjustment is required in patients with mild renal impairment (estimated glomerular filtration rate [eGFR] ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dosage adjustment is required in patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). 3. In patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2), administer 50 mg once daily. 4. In patients with severe renal impairment (estimated glomerular filtration rate [eGFR] ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (estimated glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2), administer 25 mg once daily. This medicine may be administered regardless of the timing of dialysis.

Ingredients

Manufacturer
Aliko Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

  • Type 2 diabetes
  • difficulty in blood sugar control
View approved original text

This medicine helps patients with type 2 diabetes effectively control their blood sugar in conjunction with diet and exercise therapy. It can be administered alone, and can be used by patients who have not received diabetes drug therapy before. If blood sugar control is insufficient with monotherapy, it is administered in combination with metformin. Additionally, if any one of sulfonylureas, metformin, thiazolidinediones, or insulin is ineffective on its own, this drug can be used in combination. Furthermore, even in cases where it is difficult to control blood sugar despite multiple medications, this drug may be added to the treatment regimen. Ultimately, this drug is used to improve blood sugar control in patients and assist in diabetes management.

How to take

Adult dose

This medicine is administered at a dose of 100 mg once daily, either as monotherapy or in combination therapy; the maximum daily dose is 100 mg. This medicine may be taken with or without food. When administered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). Patients with renal impairment Because dosage adjustment according to renal function is required, assessment of renal function is recommended before starting treatment with this medicine and periodically thereafter. 1. No dosage adjustment is required in patients with mild renal impairment (estimated glomerular filtration rate [eGFR] ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dosage adjustment is required in patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). 3. In patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2), administer 50 mg once daily. 4. In patients with severe renal impairment (estimated glomerular filtration rate [eGFR] ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (estimated glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2), administer 25 mg once daily. This medicine may be administered regardless of the timing of dialysis.

Precautions

This drug may rarely cause severe allergic reactions after administration; if symptoms such as skin rash or breathing difficulties occur, use should be stopped immediately and a doctor consulted. This drug may induce a condition known as acute pancreatitis, which involves inflammation of the pancreas, so if abdominal pain, vomiting, or severe abdominal discomfort occurs, it is important to visit a hospital promptly. It is considered safe not to use this drug in patients with type 1 diabetes or diabetic ketoacidosis. Patients with diminished kidney function may face an increased risk of side effects due to difficulty in excretion of this drug, so dosage adjustments or careful use is necessary. While using this drug, hypoglycemic symptoms may occur, so particularly when taken with other hypoglycemic agents such as insulin or sulfonylureas, blood glucose levels should be monitored closely. If symptoms such as joint pain or blisters on the skin appear during treatment with this drug, promptly inform a doctor and discontinue use if necessary. Women who are pregnant or breastfeeding are advised to avoid using this drug, and safety and efficacy in children or adolescents under 18 years old have not been established. Elderly patients may have impaired kidney function, so regular kidney function tests before and after taking this drug are recommended. In cases of overdose, general treatment should be administered, and if necessary, the drug may be removed via hemodialysis. This drug has relatively few interactions with other medications, but it is advisable to consult with a doctor or pharmacist when taking certain medications.

Side effects

  • Anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • hypoglycemia
  • nasopharyngitis
  • upper respiratory tract infection
  • headache
  • diarrhea
  • abdominal pain
Show 32 more
  • nausea
  • constipation
  • vomiting
  • rash
  • urticaria
  • cutaneous vasculitis
  • elevated liver enzymes
  • acute renal failure
  • severe and disabling arthralgia
  • pemphigus-like blistering
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rhabdomyolysis
  • dyspepsia
  • dizziness
  • increased ALT
  • increased AST
  • elevated serum triglycerides
  • gastritis
  • pneumonia
  • diabetes complications
  • metabolic acidosis
  • falls
  • cardiac arrest
  • weight loss
  • hypertension
  • hypernatremia
  • erectile dysfunction

Not everyone experiences these, and they can vary from person to person.

Storage

This drug should be stored in a tightly sealed container to prevent air ingress, and it is important to maintain storage temperature between 1 and 30 degrees Celsius at room temperature. This will help ensure the drug's effectiveness is safely preserved for a long time.

Appearance and packaging

Appearance

Light apricot-colored, round, biconvex film-coated tablets

Package unit

PTP - 28 tablets/box [(14 tablets/PTP×2)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.